Original Article

Cancer Immunology, Immunotherapy

, Volume 59, Issue 5, pp 769-777

First online:

Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma

  • Miki TonguAffiliated withDepartment of Immunology, Shimane University Faculty of MedicineExperimental Animal Center, Shimane University
  • , Nanae HarashimaAffiliated withDepartment of Immunology, Shimane University Faculty of Medicine
  • , Takaya YamadaAffiliated withExperimental Animal Center, Shimane University
  • , Takayuki HaradaAffiliated withDepartment of Pathology, Shimane University Faculty of Medicine
  • , Mamoru HaradaAffiliated withDepartment of Immunology, Shimane University Faculty of Medicine Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Mitigation of regulatory T cell-mediated immunosuppression and elicitation of immunogenic tumor cell death are crucial events for optimal anti-tumor immune activity in vivo. This study was designed to investigate the potential synergistic activity of the combined use of cyclophosphamide (CP) and doxorubicin (DR), both of which are known to resolve these two issues. BALB/c mice were inoculated subcutaneously with CT-26 carcinoma cells in the bilateral flank and treated with an intraperitoneal injection of a low dose of CP followed by an intratumoral injection of DR into one side of the tumor. We found that, in addition to a significant suppression of growth on the DR-treated side of the tumor, combination therapy suppressed the growth of DR-untreated remote tumors in both tumor-specific and T cell-dependent manners. Mitomycin C showed no such synergistic anti-tumor activity with CP treatment. Combination therapy increased the frequency of interferon (IFN)-γ-producing T lymphocytes specific to a CT-26-associated class I-binding tumor peptide in the tumor-draining lymph nodes. Real-time PCR analysis revealed that combination therapy led to an increase in IFN-γ and tumor necrosis factor-α mRNA expression; however, levels of Foxp3 and transforming growth factor-β within the remote tumor tissues were decreased. In addition, knock down of calreticulin expression in CT-26 cells using small interfering RNA attenuated anti-tumor vaccine effects induced by DR-treated CT-26 cells. These results provide an immunological rationale for the combined use of chemotherapeutic drugs, i.e., CP and DR, and further recommend their use with current cancer vaccines.


Cyclophosphamide Doxorubicin Regulatory T cells Calreticulin